726 results about "Intravenous Infusions" patented technology

A pump for pumping fluid includes a tube platen, a plunger, a bias member, inlet and outlet valves, an actuator mechanism, a position sensor, and a processor. The plunger is configured for actuation toward and away from the infusion-tube when the tube platen is disposed opposite to the plunger. The tube platen can hold an intravenous infusion tube. The bias member is configured to urge the plunger toward the tube platen.

We describe connectors for safely and conveniently injecting measured doses of sterile liquid medications into a patient via one or more infusion ports in intravenous access assemblies. Each connector comprises a tubular injector divided by a rigid septum which holds a hollow needle sharp on each end safely recessed in a leading and in a trailing chamber. The leading chamber snugly holds the trailing limb and penetrable cap of an inserted standard infusion port. The trailing recess snugly holds the leading end of a cartridge with a leading penetrable diaphragm, a bore containing liquid medication, a cartridge piston and trailing bore suitable for insertion of a separate cartridge plunger having markers for measuring doses delivered; or, alternatively, the pentrable cap and trailing limb of second similar infusion port attached by trailing tubing to a large measured volume infusion source. When assembled such that the trailing cap of infusion port is penetrated by the needle in the leading chamber and the leading diaphragm of the cartridge or, alternatively, the leading penetrable cap on a second infusion port is penetrated by the needle in the trailing chamber, such that flow can proceed through the needle, precisely measured doses of sterile liquid medication can be injected into the venous access assembly without possibilities for the user to touch, get stuck or finger-contaminate the needle or its contents. Unique features added to increase the efficiency of the system are a biased leading end on the tubular injector to conveniently and securely accommodate a Y-infusion port; an eccentric needle in the connector, such that rotation prevents the leading sharp end of the needle from passing through the infusion port cap via the same track; and an easily removed biased cap for keeping the cartridge diaphragm sterile.

An apparatus for monitoring the drip rate of an infusion fluid being administered by an intravenous infusion set comprising a housing, drop sensor, alarm and processor. The housing is attachable to a drip chamber, and the drop sensor is positioned in the housing to detect drops of the infusion fluid being administered by the intravenous infusion set. The processor determines a first amount of time required for the drop sensor to detect a first set of drops of infusion fluid having a predetermined number of drops, determines a second amount of time required for the drop sensor to detect a second set of drops of infusion fluid having the predetermined number of drops, compares the second amount of time to a range of time having a minimum that is less than the first amount of time and a maximum that is greater than the first amount of time, and activates the alarm if the second period of time is not within the range of time.

The invention provides an apparatus for safely storing and retrieving power cords and electronic wiring associated with a mobile intravenous pole serving patients in intensive care settings wherein a plurality of devices are required and enabling the patient to be mobile without causing power cords and wiring to become tangled and dragging on patient room or hospital floors.

The present invention relates to delivery containers designed to deliver fluids for infusion to patients in a predetermined sequence, and methods for their construction and use. The containers described herein integrally comprise a plurality of non-fluidly connected chambers. The containers may be configured to deliver a volume of each medication of an infusion therapy in a predetermined sequence, duration, and/or interval from these chambers; alternatively, a container may be part of a larger device that provides the necessary hardware to perform such predetermined delivery. The container provides improved infusion therapy administration by reducing opportunities for error, infection, adverse drug interactions, or other complications.

Liquid infusion apparatus includes non-magnetic materials in a pumping structure and ultrasonic drive motor therefor, and in a controller that supplies drive signals to the motor to facilitate convenient operation in intense magnetic fields without distorting the magnetic fields and without radiating objectionable radio-frequency interference. A non-MRI-compatible liquid infusion apparatus is temporarily replaced with MRI-compatible, non-magnetic liquid infusion apparatus without disconnecting a patient from an installed intravenous infusion set to continue infusing liquid within the MRI environment. The pumping apparatus operates on a segment of a liquid conduit that is mounted in tension between a linear peristaltic pump and platen, with associated safety interlocks to assure proper operation of infusing liquid into a patient compatibly with conditions in an MRI environment. Drive circuitry generates low-harmonic signals for operating the ultrasonic motor at variable speeds to compensate for flow rate discontinuities through the peristaltic pumping cycles.

The invention discloses an automatic dispensing robot system and an automatic dispensing method, which are used for preparing an intravenous infusion solution. The system comprises a closed cavity, wherein the closed cavity can be opened, and an input module, a powder bottle shaking module, an ampoule bottle breaking module, a disinfection module, a quantitative injection module and a visual detection and motion control module are arranged in the closed cavity. According to the automatic dispensing robot system, the breaking, disinfection and quantitative suction of an ampoule bottle, the disinfection and quantitative suction of a powder bottle and the mixing with a mother solution can be automatically realized, and the solution is prevented from being polluted; additionally, nursing personnel are prevented from being radiated and hurt by harmful substances; the probability of misoperation is reduced; the operating standard of intravenous infusion dispensing is standardized; and the dispensing efficiency is increased.

The automatic control-type, portable intravenous infusion apparatus includes an infusion liquid container to which an infusion liquid tube is connected, pressurize it, the infusion liquid tube being provided with a drip-monitoring tube, a connector and an infusion needle with a pressurizing bag for holding the infusion liquid container. The infusion liquid container includes an inflatable pressurizing bag and a sheet member having side ends each fixed to the side ends of the pressurizing bag. Connected to the pressurizing bag are an air tube provided with a mechanical safety valve, a selector valve and an air pump. By introducing air into the infusion liquid container, the pressurizing bag is inflated to apply substantially a constant pressure to the infusion liquid container, thereby flowing the infusion liquid from the container and keeping the dropping speed there substantially constant.

The invention relates to the technical field of medicine, in particular to a preparation method of nano-particles of insoluble drugs. The method includes the following steps: (1) dissolving the drugs in a first solvent (good solvent) to form solution, (2) blending the solution with a second solvent (poor solvent) to form premixed suspension, (3) applying energy on the premixed suspension to form the nano-particles, the average effective grain diameter of which is less than 2Mum. By adopting the technology combining micro-deposition and homogenization, the invention suspends the drugs in poor solvent (usually water) in a form of pure nano-crystal, thus solving the problem that solution is difficult to be prepared since the drugs are difficult to be dissolved in water and oil; compared with the corresponding injection for intravenous infusion and the oral preparations such as tablets, capsules, and the like, the preparation method of the invention can lower adverse reaction, reduce toxic and side effect, improve bioavailability, has sustained-release effect and is convenient to be used by patients.

Concentrated, low-viscosity, low-volume liquid pharmaceutical formulations of proteins have been developed. Such formulations can be rapidly and conveniently administered by subcutaneous or intramuscular injection, rather than by lengthy intravenous infusion. These formulations include low-molecular-weight and/or high-molecular-weight proteins, such as mAbs, and viscosity-lowering agents that are typically bulky polar organic compounds, such as many of the GRAS (US Food and Drug Administration List of compounds generally regarded as safe) and inactive injectable ingredients and FDA approved therapeutics.

The present invention is a safety shield assembly having a shield and a collar for connecting the shield to a fluid handling device whereby the shield may be pivoted with respect to the collar. Preferably, the safety shield assembly may be used with a needle assembly, an intravenous infusion set a syringe, a catheter or other fluid handling devices or assemblies that contain piercing elements.

Formulations and methods of use thereof for restoring neuronal, muscular (cardiac and striated) and/or retinal tissue function in children and adults afflicted with chronic neurodegenerative diseases, such as neurodegenerative movement disorders and ataxias, seizure disorders, motor neuron diseases, and inflammatory demyelinating disorders, are described herein. Examples of disorders include Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). The method involves administering a pharmaceutical composition containing an effective amount of a tetrahydrobenzathiazole, preferably a formulation consisting substantially of the R(+) enantiomer of pramipexole. R(+) pramipexole is generally administered in doses ranging from 0.1-300 mg/kg/daily, preferably 0.5-50 mg/kg/daily, and most preferably 1-10 mg/kg/daily for oral administration. Daily total doses administered orally are typically between 10 mg and 500 mg. Alternatively, R(+) pramipexole can be administered parenterally to humans with acute brain injury in single doses between 10 mg and 100 mg and/or by continuous intravenous infusions between 10 mg/day and 500 mg/day.

Prostacyclin compounds and compositions comprising the same are provided herein. Specifically, prostacyclin compounds comprising treprostinil covalently linked to a linear C₂-C₁₈ alkyl, branched C₃-C₁₈ alkyl, linear C₂-C₁₈ alkenyl, branched C₃-C₁₈ alkenyl, aryl, aryl-C₁-C₁₈ alkyl or an amino acid or a peptide (e.g., dipeptide, tripeptide, tetrapeptide) are described, for example, for administration via subcutaneous or intravenous infusion to a patient in need of pulmonary hypertension treatment. The linkage, in one embodiment, is via a carbamate, amide or ester bond. Prostacyclin compounds provided herein can also include at least one hydrogen atom substituted with at least one deuterium atom.

Formulations and methods of use thereof for restoring neuronal tissue function in children and adults afflicted with chronic neurodegenerative diseases, such as neurodegenerative movement disorders and ataxias, seizure disorders, motor neuron diseases, and inflammatory demyelinating disorders. Examples of disorders include Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). The method involves administering a pharmaceutical composition containing an effective amount of a tetrahydrobenzathiazole, preferably a formulation consisting substantially of the R(+) enantiomer of pramipexole. R(+) pramipexole is generally administered in doses ranging from 0.1-300 mg/kg/daily, preferably 0.5-50 mg/kg/daily, and most preferably 1-10 mg/kg/daily for oral administration. Daily total doses administered orally are typically between 10 mg and 500 mg. Alternatively, R(+) pramipexole can be administered parenterally to humans with acute brain injury in single doses between 10 mg and 100 mg, and/or by continuous intravenous infusions between 10 mg/day and 500 mg/day.

Concentrated, low-viscosity, low-volume liquid pharmaceutical formulations of proteins have been developed. Such formulations can be rapidly and conveniently administered by subcutaneous or intramuscular injection, rather than by lengthy intravenous infusion. These formulations include low-molecular-weight and/or high-molecular-weight proteins, such as mAbs, and viscosity-lowering water soluble organic dyes.

A method of reducing the occurrence of brain cell damage or death caused by transient cerebral hypoxia/ischemia condition or a traumatic brain injury (TBI) event. The method typically comprises identifying a subject with a transient cerebral hypoxic and/or ischemic condition, or a TBI, and within 24 hours of onset of the condition, administering to the subject a continuous intravenous infusion dose of methamphetamine in an amount sufficient to reduce the occurrence of brain cell damage or death caused by the condition. Preferably, in addition to the continuous intravenous infusion dose, a bolus dose of methamphetamine is administered to the subject as soon as possible after onset of the condition or occurrence of the TBI event.

The invention discloses an automatic exhaust medicinal intravenous infusion set, which comprises a liquid inlet assembly, a dropping funnel, a liquid outlet assembly and a disposable intravenous injection needle which are connected in turn. A dropping funnel cover covers an opening of the dropping funnel in a sealing mode and a dropping tube and a liquid medicine injection part are arranged on the dropping funnel cover; and an automatic exhaust assembly is integrally arranged on the side wall of the dropping funnel and comprises a vent hole, a hole cover and a ventilated filtering membrane, wherein the vent hole is integrally molded with the side wall of the dropping funnel; the hole cover comprises a cap capable of opening and closing; and the ventilated filtering membrane is positioned between the hole cover and the contact surface of the vent hole and does not exhaust liquid but air. By ingeniously adopting a structure of integrally arranging the automatic exhaust assembly on the side wall of the dropping tube, the automatic exhaust medicinal intravenous infusion set has the advantages of effectively guaranteeing that the dropping funnel cover has the sealing performance of the conventional common intravenous injector, reducing the operating difficulty of medical care personnel, greatly reducing the probability of existing and accumulating air bubbles in an inner cavity of the dropping funnel, efficiently and reliably exhausting the air bubbles in the dropping funnel completely, fully guaranteeing the safety and reliability for infusion, along with simple structure, easy manufacture and high practicality.